

obligations under the Hague Convention, which is the substance in S. 2883.

This measure has the support of the relevant House and Senate Committees and the Departments of State and Justice. If this measure is not enacted into law, NCMC may not be able to continue its operations on behalf of the Federal Government since its resources would be lost in the defense of frivolous lawsuits. Left-behind parents would suffer the prolonged loss of their children, and our Nation potentially would lose its advantage in pressing other nations to return abducted children.

I wish to extend my personal gratitude to the National Center for Missing and Exploited Children for its critical work on reuniting families, to Chairman JIM SENSENBRENNER of the House Judiciary Committee, and to Senators HATCH and LEAHY of the Senate Judiciary Committee and to Senators LUGAR and BIDEN of the Senate Foreign Relations Committee, for working tirelessly to implement this measure.

GENERAL LEAVE

Mr. CANNON. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days within which to revise and extend their remarks and include extraneous material on S. 2883.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from Utah?

There was no objection.

ANABOLIC STEROID CONTROL ACT OF 2004

Mr. CANNON. Mr. Speaker, I ask unanimous consent to take from the Speaker's table the Senate bill (S. 2195) to amend the Controlled Substances Act to clarify the definition of anabolic steroids and to provide for research and education activities relating to steroids and steroid precursors, and ask for its immediate consideration in the House.

The Clerk read the title of the Senate bill.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from Utah?

There was no objection.

The Clerk read the Senate bill, as follows:

S. 2195

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "Anabolic Steroid Control Act of 2004".

SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.

(a) DEFINITIONS.—Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended—

(1) in paragraph (41)—

(A) by realigning the margin so as to align with paragraph (40); and

(B) by striking subparagraph (A) and inserting the following:

“(A) The term ‘anabolic steroid’ means any drug or hormonal substance, chemically and pharmacologically related to testosterone

(other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes—

“(i) androstenediol—

“(I) 3 β ,17 β -dihydroxy-5 α -androstane; and

“(II) 3 α ,17 β -dihydroxy-5 α -androstane;

“(ii) androstanedione (5 α -androstane-3,17-dione);

“(iii) androstenediol—

“(I) 1-androstenediol (3 β ,17 β -dihydroxy-5 α -androst-1-ene);

“(II) 1-androstenediol (3 α ,17 β -dihydroxy-5 α -androst-1-ene);

“(III) 4-androstenediol (3 β ,17 β -dihydroxy-androst-4-ene); and

“(IV) 5-androstenediol (3 β ,17 β -dihydroxy-androst-5-ene);

“(iv) androstenedione—

“(I) 1-androstenedione ([5 α]-androst-1-en-3,17-dione);

“(II) 4-androstenedione (androst-4-en-3,17-dione); and

“(III) 5-androstenedione (androst-5-en-3,17-dione);

“(v) bolasterone (7 α ,17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);

“(vi) boldenone (17 β -hydroxyandrost-1,4-diene-3-one);

“(vii) calusterone (7 β ,17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);

“(viii) clostebol (4-chloro-17 β -hydroxyandrost-4-en-3-one);

“(ix) dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methyl-androst-1,4-dien-3-one);

“(x) Δ 1-dihydrotestosterone (a.k.a. ‘1-testosterone’) (17 β -hydroxy-5 α -androst-1-en-3-one);

“(xi) 4-dihydrotestosterone (17 β -hydroxy-androstane-3-one);

“(xii) drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstane-3-one);

“(xiii) ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);

“(xiv) fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);

“(xv) formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-one);

“(xvi) furazabol (17 α -methyl-17 β -hydroxyandrostano[2,3-c]-furan);

“(xvii) 13 β -ethyl-17 α -hydroxygon-4-en-3-one;

“(xviii) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);

“(xix) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);

“(xx) mestanolone (17 α -methyl-17 β -hydroxy-5 α -androstane-3-one);

“(xxi) mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstane-3-one);

“(xxii) methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);

“(xxiii) methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);

“(xxiv) methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);

“(xxv) 17 α -methyl-3 β , 17 β -dihydroxy-5 α -androstane;

“(xxvi) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane;

“(xxvii) 17 α -methyl-3 β ,17 β -dihydroxy-androst-4-ene.

“(xxviii) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-en-3-one);

“(xxix) methylidenolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);

“(xxx) methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);

“(xxxi) methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);

“(xxxii) mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);

“(xxxiii) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one) (a.k.a. ‘17 α -methyl-1-testosterone’);

“(xxxiv) nandrolone (17 β -hydroxyestr-4-en-3-one);

“(xxxv) norandrostenediol—

“(I) 19-nor-4-androstenediol (3 β , 17 β -dihydroxyestr-4-ene);

“(II) 19-nor-4-androstenediol (3 α , 17 β -dihydroxyestr-4-ene);

“(III) 19-nor-5-androstenediol (3 β , 17 β -dihydroxyestr-5-ene); and

“(IV) 19-nor-5-androstenediol (3 α , 17 β -dihydroxyestr-5-ene);

“(xxxvi) norandrostenedione—

“(I) 19-nor-4-androstenedione (estr-4-en-3,17-dione); and

“(II) 19-nor-5-androstenedione (estr-5-en-3,17-dione);

“(xxxvii) norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);

“(xxxviii) norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);

“(xxxix) norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);

“(xl) normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);

“(xli) oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstane-3-one);

“(xlii) oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);

“(xliii) oxymetholone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androstane-3-one);

“(xliv) stanozolol (17 α -methyl-17 α -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);

“(xlv) stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);

“(xlvii) testosterone (13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oic acid lactone);

“(xlviii) testosterone (17 β -hydroxyandrost-4-en-3-one);

“(xlviii) tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);

“(xlix) trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one); and

“(xl) any salt, ester, or ether of a drug or substance described in this paragraph.

The substances excluded under this subparagraph may at any time be scheduled by the Attorney General in accordance with the authority and requirements of subsections (a) through (c) of section 201; and

(2) in paragraph (44), by inserting “anabolic steroids,” after “marihuana,”.

(b) AUTHORITY AND CRITERIA FOR CLASSIFICATION.—Section 201(g) of the Controlled Substances Act (21 U.S.C. 811(g)) is amended—

(1) in paragraph (1), by striking “substance from a schedule if such substance” and inserting “drug which contains a controlled substance from the application of titles II and III of the Comprehensive Drug Abuse Prevention and Control Act (21 U.S.C. 802 et seq.) if such drug”; and

(2) in paragraph (3), by adding at the end the following:

“(C) Upon the recommendation of the Secretary of Health and Human Services, a compound, mixture, or preparation which contains any anabolic steroid, which is intended for administration to a human being or an animal, and which, because of its concentration, preparation, formulation or delivery system, does not present any significant potential for abuse.”.

(c) ANABOLIC STEROIDS CONTROL ACT.—Section 1903 of the Anabolic Steroids Control Act of 1990 (Public Law 101-647) is amended—

(1) by striking subsection (a); and

(2) by redesignating subsections (b) and (c) as subsections (a) and (b), respectively.

(d) EFFECTIVE DATE.—The amendments made by this section shall take effect 90 days after the date of enactment of this Act.

SEC. 3. SENTENCING COMMISSION GUIDELINES.

The United States Sentencing Commission shall—